D. de Jong

Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay

Charles A. Boucher, Wilco Keulen, Toon van Bommel et al. · Antimicrobial Agents and Chemotherapy · 1996 · 85 citations · Full text

Drug Susceptibility, Hiv-1 Rna, Medicine +15

Quantum Enhancement of the Index of Refraction in a Bose-Einstein Condensate

Pieter Bons, Ralph De Haas, D. de Jong et al. · Physical Review Letters · 2016 · 40 citations · Full text

A novel real-time PCR assay to determine relative replication capacity for HIV-1 protease variants and/or reverse transcriptase variants

Noortje M. van Maarseveen, Marleen C.D.G. Huigen, D. de Jong et al. · Journal of Virological Methods · 2005 · 35 citations

Viral Replication, Engineering, Relative Replication Capacity +13

Therapy Failure following Selection of Enfuvirtide‐Resistant HIV‐1 in Cerebrospinal Fluid

S.F.L. van Lelyveld, Monique Nijhuis, Franky Baatz et al. · Clinical Infectious Diseases · 2010 · 30 citations · Full text

Immunology, Antiviral Drug, Therapy Failure +16

Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient

Jori Symons, S.F.L. van Lelyveld, A. I. M. Hoepelman et al. · Journal of Antimicrobial Chemotherapy · 2011 · 29 citations · Full text